Table 1.
Demographic data, extracorporeal therapies and microbiological data.
| Case | Sex | Age [years] | Weight [kg] | CKD-EPI eGFR (mL/min/1.73 m2) or Mode of Renal Replacement Therapy | Cefiderocol Dose [mg/24 h] | Cefiderocol Trough Level [mg/L] | Focus of Infection | SOFA/SAPS | Medical History | Outcome Related to the Event | Pathogen Isolated | MIC [mg/L] | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First Available Isolate | Last Available Isolate | ||||||||||||
| 1 | m | 35 | 75 | CVVHD DFR 2.0 L/min * | 2000 | 25.2 (day 2) | CAP | 11/49 | PAH; interstitial lung disease; chronic renal impairment | CC + MC | P. aeruginosa | 0.5 | 0.25 |
| CVVHD DFR 2.0 L/min * | 2000 | 32.0 (day 4) | |||||||||||
| 2 | f | 60 | 60 | 67 | 3000 | 70 (day 1) | HAP | 4/33 | Esophagectomy, IPA, mediastinitis | MC | P. aeruginosa | 0.25 | n.a. |
| 22 | 2000 | 49 (day 7) | |||||||||||
| 3 | m | 76 | 85 | 84 | 6000 | 36.8 (day 1) | HAP; Primary Sepsis | 9/49 | COVID-19; ARDS, ECMO | MC | A. baumannii | 0.25 | 0.25 |
| 85 | 6000 | 43.2 (day 3) | |||||||||||
| 81 | 6000 | 59.5 (day 4) | |||||||||||
| 4 | m | 53 | 60 | 28 | 6000 | 42 (day 1) | Primary Sepsis | 14/68 | ASCT; GvHD c/I; invasive mold infection; HHV-6 encephalitis; BKV-cystitis | died | P. aeruginosa | 0.125 | 16 |
| CVVHD DFR 2.4 L/min * | 3000 | >100 (day 3) | |||||||||||
| 5 | m | 55 | 90 | CVVHD DFR 2.4 L/min * + CytoSorb® ** |
6000 | 26 (day 1) 13 (day 2) |
HAP | 19/59 | COVID-19; ARDS, ECMO | died | A. baumannii | 0.25 | n.a. |
ARDS = acute respiratory distress syndrome; ASCT = allogenic stem cell transplantation; BKV = human papilloma virus; CAP = community acquired pneumonia; CC = clinical cure; COVID-19 = Coronavirus disease 19; CVVHD = continuous venovenous haemodialysis; DFR = dialysate flow rate; eGFR = estimated glomerular filtration rate calculated by CKD-EPI; f = female; GvHD c/l = graft-versus-host disease cutaneous/lung; HAP = hospital acquired pneumonia; HHV-6 = human herpes virus 6; IPA = invasive pulmonary aspergillosis; m= male; MC = microbiological cure; MIC = minimal inhibitory concentration; n.a. = not applicable; SAPS = simplified acute physiology score; SOFA = sequential organ failure assessment; PAH = pulmonary hypertension; * used with the Ultraflux V600S filter with a 1.4 m2 surface area (Fresenius Medical Care, Germany); ** installed in series with the CVVHD, with a blood flow of 200 mL/min (CytoSorbents Corporation, Monmouth Junction, NJ, USA).